A Phase 3 interventional study of ATX-101 and Placebo in Submental Fat and Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 15 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.
Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The investigation of the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.
No study medication is administered in this study.
Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Kythera Biopharmaceuticals became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
Drug: ATX-101
Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
Drug: Placebo
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Percentage of Participants Maintaining CR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment.
Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Percentage of Participants Maintaining PR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
The objective of this non-treatment, double-blind, placebo-controlled follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study.
| Milestone | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Started | 113 | 111 |
| Completed | 102 | 98 |
| Not completed | 11 | 13 |
| Withdrew: Subject's request | 3 | 4 |
| Withdrew: Lost to follow-up | 6 | 7 |
| Withdrew: Administrative decision | 2 | 2 |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 86.4 (79.2 to 93.5) | 56.8 (42.2 to 71.5) |
| Visit 2 (Year 2) Percentage | 90.6 (84.4 to 96.8) | 73.8 (60.5 to 87.1) |
| Visit 3 (Year 3) Percentage | 82.4 (74.2 to 90.5) | 65.0 (50.2 to 79.8) |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 75.0 (61.6 to 88.4) | 18.2 (0.0 to 41.0) |
| Visit 2 (Year 2) Percentage | 72.5 (58.7 to 86.3) | 33.3 (2.5 to 64.1) |
| Visit 3 (Year 3) Percentage | 65.8 (50.7 to 80.9) | 33.3 (2.5 to 64.1) |
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 95.5 (91.1 to 99.8) | 76.4 (65.1 to 87.6) |
| Visit 2 (Year 2) Percentage | 87.8 (81.0 to 94.5) | 83.0 (72.9 to 93.1) |
| Visit 3 (Year 3) Percentage | 77.0 (68.2 to 85.9) | 75.0 (62.8 to 87.2) |
The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 59.0 (43.5 to 74.4) | 63.6 (35.2 to 92.1) |
| Visit 2 (Year 2) Percentage | 57.5 (42.2 to 72.8) | 60.0 (29.6 to 90.4) |
| Visit 3 (Year 3) Percentage | 59.5 (43.6 to 75.3) | 70.0 (41.6 to 98.4) |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 86.8 (79.2 to 94.4) | 44.8 (26.7 to 62.9) |
| Visit 2 (Year 2) Percentage | 85.1 (77.0 to 93.2) | 64.3 (46.5 to 82.0) |
| Visit 3 (Year 3) Percentage | 72.6 (62.4 to 82.8) | 46.2 (27.0 to 65.3) |
The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.
| percentage of participants | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| Visit 1 (Year 1) Percentage | 41.2 (17.8 to 64.6) | 0.0 (NA to NA) |
| Visit 2 (Year 2) Percentage | 43.8 (19.4 to 68.1) | 0.0 (NA to NA) |
| Visit 3 (Year 3) Percentage | 50.0 (23.8 to 76.2) | 50.0 (0.0 to 100.0) |
Collected over From the first exposure to study drug in predecessor study to up to 36 months after last treatment in predecessor study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATX-101 (Deoxycholic Acid) Injection | 0/113 (0%) | 5/113 (4.4%) | 0/113 (0%) |
| Placebo | 0/111 (0%) | 1/111 (0.9%) | 0/111 (0%) |
| Event | ATX-101 (Deoxycholic Acid) Injection | Placebo |
|---|---|---|
| DiverticulitisGastrointestinal disorders | 2/113 | 0/111 |
| Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/96 | 1/95 |
| Breast reconstructionSurgical and medical procedures | 1/96 | 0/95 |
| Ovarian cancer recurrentReproductive system and breast disorders | 1/96 | 0/95 |
| Small cell lung cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/113 | 0/111 |
| Age, Continuous(years) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 51.0 ± 8.22 | 50.1 ± 9.00 | 50.6 ± 8.61 |
| Age, Customized(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| ≤ 30 years | 3 | 4 | 7 |
| > 30 to ≤ 50 years | 52 | 49 | 101 |
| > 50 years | 58 | 58 | 116 |
| < 50 years | 47 | 47 | 94 |
| Sex: Female, Male(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Female | 96 | 95 | 191 |
| Male | 17 | 16 | 33 |
| Ethnicity (NIH/OMB)(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 33 | 25 | 58 |
| Not Hispanic or Latino | 80 | 86 | 166 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 4 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 12 | 7 | 19 |
| White | 96 | 101 | 197 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| Mean | 29.283 ± 4.4934 | 28.836 ± 4.0099 | 29.062 ± 4.2570 |
| Fitzpatrick Score(Participants) | ATX-101 (Deoxycholic Acid) Injection | Placebo | Total |
|---|---|---|---|
| I | 4 | 4 | 8 |
| II | 30 | 39 | 69 |
| III | 33 | 36 | 69 |
| IV | 35 | 20 | 55 |
| V | 9 | 9 | 18 |
| VI | 2 | 3 | 5 |
The record gives a start of Dec 2013, a primary completion of Jan 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2020, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101